Xenon Pharmaceuticals Statistics

Total Valuation

XENE has a market cap or net worth of $2.90 billion. The enterprise value is $2.28 billion.

Market Cap	2.90B
Enterprise Value	2.28B

Important Dates

The last earnings date was Monday, August 11, 2025, after market close.

Earnings Date	Aug 11, 2025
Ex-Dividend Date	n/a

Share Statistics

XENE has 76.94 million shares outstanding. The number of shares has increased by 7.80% in one year.

Current Share Class	76.94M
Shares Outstanding	76.94M
Shares Change (YoY)	+7.80%
Shares Change (QoQ)	+0.34%
Owned by Insiders (%)	0.14%
Owned by Institutions (%)	100.78%
Float	71.09M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	386.44
Forward PS	n/a
PB Ratio	4.69
P/TBV Ratio	4.57
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	n/a
EV / Sales	304.29
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 15.14, with a Debt / Equity ratio of 0.01.

Current Ratio	15.14
Quick Ratio	14.75
Debt / Equity	0.01
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	n/a

Financial Efficiency

Return on equity (ROE) is -37.65% and return on invested capital (ROIC) is -26.57%.

Return on Equity (ROE)	-37.65%
Return on Assets (ROA)	-25.52%
Return on Invested Capital (ROIC)	-26.57%
Return on Capital Employed (ROCE)	-49.61%
Revenue Per Employee	$22,936
Profits Per Employee	-$850,850
Employee Count	327
Asset Turnover	0.01
Inventory Turnover	n/a

Taxes

Income Tax	-4.37M
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -3.04% in the last 52 weeks. The beta is 1.16, so XENE's price volatility has been higher than the market average.

Beta (5Y)	1.16
52-Week Price Change	-3.04%
50-Day Moving Average	32.18
200-Day Moving Average	36.23
Relative Strength Index (RSI)	74.73
Average Volume (20 Days)	1,044,065

Short Selling Information

The latest short interest is 6.97 million, so 9.07% of the outstanding shares have been sold short.

Short Interest	6.97M
Short Previous Month	6.51M
Short % of Shares Out	9.07%
Short % of Float	9.81%
Short Ratio (days to cover)	4.31

Income Statement

In the last 12 months, XENE had revenue of $7.50 million and -$278.23 million in losses. Loss per share was -$3.54.

Revenue	7.50M
Gross Profit	-202.89M
Operating Income	-318.12M
Pretax Income	-199.34M
Net Income	-278.23M
EBITDA	-315.49M
EBIT	-318.12M
Loss Per Share	-$3.54

Full Income Statement

Balance Sheet

The company has $487.55 million in cash and $8.72 million in debt, giving a net cash position of $616.13 million or $8.01 per share.

Cash & Cash Equivalents	487.55M
Total Debt	8.72M
Net Cash	616.13M
Net Cash Per Share	$8.01
Equity (Book Value)	633.98M
Book Value Per Share	8.03
Working Capital	467.21M

Full Balance Sheet

Cash Flow

Operating Cash Flow	n/a
Capital Expenditures	n/a
Free Cash Flow	n/a
FCF Per Share	n/a

Full Cash Flow Statement

Margins

Gross Margin	n/a
Operating Margin	-4,241.60%
Pretax Margin	-3,767.93%
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

XENE does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-7.80%
Shareholder Yield	-7.80%
Earnings Yield	-9.60%
FCF Yield	n/a

Dividend Details

Analyst Forecast

The average price target for XENE is $53.20, which is 41.23% higher than the current price. The consensus rating is "Strong Buy".

Price Target	$53.20
Price Target Difference	41.23%
Analyst Consensus	Strong Buy
Analyst Count	10
Revenue Growth Forecast (5Y)	n/a
EPS Growth Forecast (5Y)	-26.05%

Stock Forecasts

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Altman Z-Score	n/a
Piotroski F-Score	n/a